Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum SQI Diagnostics Inc SQIDF


Primary Symbol: V.SQD.H

SQI Diagnostics Inc. is a Canada-based company that is focused on lung health. The Company is engaged in the development and manufacturing of respiratory health and precision medicine tests that run on its fully automated systems. Its clinical solutions include Rapid Acute Lung Injury Diagnostic (RALI-Dx), lung transplant diagnostics, COVID-19 testing and surveillance testing solutions. Its... see more

TSXV:SQD.H - Post Discussion

SQI Diagnostics Inc > Endorsement of SQI technology and products comes from....
View:
Post by FactFinder1994 on Jun 09, 2023 12:47pm

Endorsement of SQI technology and products comes from....

The endorsement of SQI's products come from that of Dr. Shaf Keshavjee and his team at UHN.  These are among the top Key Opinion Leaders in Lung Transplant and respiratory health worldwide.  They along with partners have created an ecosystem and SQI is among the chosen ones for advancement given its unique technology.  There is great value for all with the synergies Dr. Shaf Keshavjee has fostered.  If you listen the Shaf, he has spoken about the great need for personalized medicine/therapy, and that is why he appreciates so dearly what SQI brings to the table.  Reliable, time sensitive, and quantitative data drives optimal decision making and supports the ecosystem for greather volume and success.  Win-Win-Win....       

Dr. Shaf Keshavjee is a world-renowned thoracic surgeon-scientist with a history of breakthroughs and discoveries in lung transplantation. He is the current Surgeon-in-Chief of the Sprott Department of Surgery, the Director of the Toronto Lung Transplant Program and Latner Thoracic Research Laboratories at UHN, and Professor of Thoracic Surgery at the University of Toronto.

Dr. Keshavjee completed his medical training at the University of Toronto in 1985, and specialized in General Surgery, Cardiac Surgery and Thoracic Surgery. He participated in the world’s first successful double lung transplant at Toronto General Hospital in 1986. Dr. Keshavjee completed fellowships at Harvard University and the University of London. During his Master’s studies, Dr. Keshavjee developed a lung preservation solution for donor lungs that has now been translated into clinical use around the world. Since then, he has led the development and translation of many innovations to the clinic, including the Ex Vivo Lung Perfusion (EVLP) system.

For Dr. Keshavjee’s achievements and leadership in the field, he has been appointed as an Officer of the Order of Canada, the country’s highest civilian honour that recognizes outstanding achievement, dedication to the community and service to the nation. Furthermore, he is a member of the Order of Ontario and has been awarded two Queen Elizabeth II Diamond Jubilee Medals. In 2020, he received the prestigious Governor General of Canada’s Innovation Award. Other notable recognitions include UHN's Inventor of the Year Award, Canada’s Top 40 Under 40, and the Lifetime Achievement Award from the Canadian Society of Transplantation.  
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities